GSK plc
Research GSK plc (GS71) on Bullrun: valuation model: 31.0% undervalued, market cap EUR 91.51B, P/E 13.8, dividend yield 3.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGS71
- ExchangeXETRA
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyEUR
- Valuation signal31.0% undervalued
- Market capEUR 91.51B
- P/E13.8
- Dividend yield3.4%
- Financial periodFY2025
- RevenueGBP 32.67B
- Revenue growth4.1%
- Net incomeGBP 6.29B
- Free cash flowGBP 6.39B
- Gross margin72.4%
Valuation Snapshot
Bullrun's latest valuation model marks GSK plc as 31.0% undervalued; latest market cap is EUR 91.51B; P/E is 13.8; dividend yield is 3.4%.
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Frequently asked questions
Is GSK plc overvalued or undervalued?
Bullrun's valuation model currently marks GSK plc as 31.0% undervalued.
What is GSK plc's market cap?
GSK plc's market capitalization is EUR 91.51B.
What is GSK plc's P/E ratio?
GSK plc's price-to-earnings (P/E) ratio is 13.8.
Does GSK plc pay a dividend?
GSK plc has a dividend yield of 3.4%.
What does GSK plc do?
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.